ANTIPLATELET AGENTS AND CARDIOVASCULAR PR EVENTION

The main contributions of meta-analysis methodology to antiplatelet th erapy in the field of cardiovascular prevention are presented with reg ard to the different sectors of the health system: help with therapeut ic information, help in the planning of clinical trials for the pharma ceutical industry and help in decision-making for Health Authorities. The results of meta-analysis of available data concerning aspirin in c ardio-vascular prevention are discussed, in an attempt to define optim al daily dose and duration of aspirin treatment.